SCHEMBL16396343

SCHEMBL16396343

COCc1cc(COc2ccccc2CC(=O)O)cc(-c2cccc(C(N)CF)c2F)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 19/20 0.61
▸ F11 P03951 10/20 0.61
▸ TPSB2 P20231 9/20 0.61
▸ KLKB1 P03952 3/20 0.48
▸ PLG P00747 2/20 0.48
▸ PLAU P00749 2/20 0.48
▸ F7 P08709 2/20 0.48
▸ PTGER1 P34995 1/20 0.45
▸ PTGER4 P35408 1/20 0.45
▸ PTGER3 P43115 1/20 0.45
▸ PTGER2 P43116 1/20 0.45
▸ F2 P00734 1/20 0.41
▸ F9 P00740 1/20 0.41
▸ F10 P00742 1/20 0.41
▸ PLAT P00750 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ SLC18A2 Q05940 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396494 0.91 CFD (0.61) CFDF11TPSB2KLKB1PLG
SCHEMBL16396215 0.91 CFD (0.61) CFDF11TPSB2KLKB1PLG
SCHEMBL16396495 0.91 CFD (0.61) CFDF11TPSB2KLKB1PLG
SCHEMBL16410462 0.90 CFD (0.52) CFDF11TPSB2KLKB1PLG
SCHEMBL16410523 0.89 CFD (0.49) CFDF11TPSB2KLKB1PLG
SCHEMBL16396368 0.89 CFD (0.61) CFDF11TPSB2KLKB1PLG
SCHEMBL16396648 0.87 CFD (0.50) CFDF11TPSB2KLKB1PLG
SCHEMBL17764376 0.86 CFD (0.49) CFDF11TPSB2KLKB1PLG
SCHEMBL17802684 0.85 CFD (0.70) CFDF11TPSB2KLKB1PLG
SCHEMBL16396683 0.84 CFD (0.49) CFDF11TPSB2KLKB1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885F11 17/4885TPSB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback